Investigational New Drug Regulations

ICR 200905-0910-005

OMB: 0910-0014

Federal Form Document

Forms and Documents
Document
Name
Status
Supporting Statement A
2009-07-23
IC Document Collections
IC ID
Document
Title
Status
5669
Modified
189367
New
189366
New
189365
New
189364
New
189363
New
189362
New
189361
New
189360
New
189359
New
189358
New
189357
New
189356
New
189355
New
189354
New
189353
New
189352
New
189351
New
189350
New
189349
New
189348
New
189347
New
189346
New
189345
New
189344
New
189343
New
189342
New
189341
New
189340
New
189339
New
189338
New
189337
New
189336
New
189335
New
189334
New
189333
New
189332
New
189331
New
189330
New
189329
New
189328
New
189327
New
189326
New
189325
New
189324
New
189323
New
189322
New
189321
New
189320
New
189319
New
189318
New
189317
New
189316
New
189315
New
189314
New
189313
New
189312
New
189311
New
ICR Details
0910-0014 200905-0910-005
Historical Active 200602-0910-005
HHS/FDA
Investigational New Drug Regulations
Extension without change of a currently approved collection   No
Regular
Approved with change 08/06/2009
Retrieve Notice of Action (NOA) 05/28/2009
This ICR is approved consistent with revised supporting statement. This ICR does not reflect any burden changes as a result of the expanded access or charging final rules. We understand that FDA plans to cover those incremental burden changes in a separate ICR. Prior to next submission, FDA agrees to reconcile the cost and burden estimates in that separate ICR with the cost and burden estimates in this ICR, and then discontinue that separate ICR.
  Inventory as of this Action Requested Previously Approved
08/31/2011 36 Months From Approved 08/31/2009
2,744,640 0 1,277,517
141,492,162 0 71,369,525
0 0 0

Information collection from applicants who apply for approval of an investigational new drug application in order to develop a drug for marketing.

US Code: 21 USC 355(i) Name of Law: FFDCA
  
None

Not associated with rulemaking

  74 FR 6889 02/11/2009
74 FR 21690 05/08/2009
No

58
IC Title Form No. Form Name
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations
Investigational New Drug Regulations

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 2,744,640 1,277,517 0 0 1,467,123 0
Annual Time Burden (Hours) 141,492,162 71,369,525 0 0 70,122,637 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No

$63,679,000
No
No
Uncollected
Uncollected
No
Uncollected
Eliazabeth Berbakos 3018271482

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
05/28/2009


© 2024 OMB.report | Privacy Policy